Understanding
What decades of research has taught us about brain health and dementia risk
Discover how Insight 46, part-funded by Alzheimer’s Research UK, has transformed our understanding of brain health and dementia risk.
Scientists discover mechanism for brain cell death in Alzheimer’s disease
Researchers at King’s College London and the UK Dementia Research Institute have uncovered evidence of a newly identified mechanism of cell death, known as karyoptosis, which could open the door to entirely new treatments aimed at slowing or preventing neurodegeneration.
Global snapshot of Alzheimer’s research offers new hope
Every year, world‑leading dementia researcher Dr Jeffrey Cummings releases a global snapshot of Alzheimer’s trials – and the 2026 update has just been published.
10 possible signs of dementia you shouldn’t ignore
It’s normal for our memory and thinking to slow down as we get older. But for some people, these changes can start to get in the way of day-to-day life. This can be a sign that something else is going on, rather than just ageing.
APOE4 and APOE3 gene variants linked to at least 7 in 10 Alzheimer’s cases, study suggests
A new study into the APOE gene suggests two variants may influence Alzheimer’s and dementia risk more than previously thought.
How nerve cells fight back against frontotemporal dementia (FTD)
Dr Teresa Niccoli’s new research looks at why some nerve cells are resilient against frontotemporal dementia (FTD)
How studying sleep in Down’s syndrome is uncovering clues about Alzheimer’s disease
We’re celebrating Join Dementia Research’s 10th Anniversary. Join Dementia Research is a service run by the NHS that allows people to register their interest in taking part in dementia research studies. Over the past decade, Join Dementia Research has supported an incredible 93,000 people to take part in over 900 dementia research studies. Alzheimer’s Research…
Scotland says no to Alzheimer’s drug lecanemab
Lecanemab – the first drug to slow down early-stage Alzheimer’s disease – will not be available on the NHS in Scotland
New Alzheimer’s treatment, lecanemab, makes the headlines: what’s next?
Alzheimer’s treatment lecanemab is the first drug that slows down the physical progression of the disease, and also symptom progression. We have compiled your most commonly asked questions and some answers about this historic news
Inheriting two copies of APOE4 linked to risk of Alzheimer’s at a younger age, study suggests
A new study confirms that people who carry two copies of an Alzheimer’s risk gene, APOE4, have a very high chance of developing Alzheimer’s.
